TGM2 and cancer: This contrasts with reported TG2 upregulation in hypoxic cancer cells, where it activates the insulin-like growth factor 1 receptor beta (IGF1Rβ)/PI3K/AKT signaling pathway, which in turn facilitates the process of epithelial-mesenchymal transition (EMT) (Kim et al., 2018).